Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | GBA1 | P04062 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28145005 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL209165 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL3712080 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL3712541 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL2377987 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL2504504 | 1.00 | CA2 (0.42) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL23541364 | 0.78 | FUCA1 (0.48) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL12556709 | 0.78 | FUCA1 (0.48) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL11962132 | 0.78 | FUCA1 (0.48) | CA2CA9CA12FUCA1SMN1; SMN2 | |
| SCHEMBL22923476 | 0.78 | FUCA1 (0.48) | CA2CA9CA12FUCA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101643-A1 | FUNGAL PROTEASES | CODEXIS INC (US) | 2017-04-13 | — | — | US | claimed |
| US-20160333329-A1 | FUNGAL PROTEASES | CODEXIS INC (US) | 2016-11-17 | — | — | US | claimed |
| US-20160075990-A1 | FUNGAL PROTEASES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2016-03-17 | — | — | US | claimed |
| EP-2760997-A1 | FUNGAL PROTEASES | Codexis, Inc. (US) | 2014-08-06 | — | — | EP | claimed |
| WO-2013048661-A1 | FUNGAL PROTEASES | CODEXIS, INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20130084608-A1 | FUNGAL PROTEASES | CODEXIS, INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8236551-B2 | Compositions and methods for production of fermentable sugars | CODEXIS, INC. (US) | 2012-08-07 | — | — | US | claimed |
| US-20060166335-A1 | Glucuronofucan sulfate | TAKARA BIO INC. (JP) | 2006-07-27 | — | — | US | claimed |
| US-20030186389-A1 | Glucuronofucan sulfate | TAKARA BIO INC. (JP) | 2003-10-02 | — | — | US | claimed |
| EP-1277834-A1 | GLUCURONOFUCAN SULFATE | TAKARA BIO INC. (JP) | 2003-01-22 | — | — | EP | claimed |
| EP-4398255-A2 | METHODS, SYSTEMS, AND SOFTWARE FOR IDENTIFYING BIO-MOLECULES WITH INTERACTING COMPONENTS | Codexis, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118302171-A | Lymphocyte populations and methods for producing the same | AVM生物技术有限责任公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11987649-B2 | Wet milling process | NOVOZYMES A/S (DK) | 2024-05-21 | — | — | US | disclosed |
| EP-3423577-B1 | CELLOBIOHYDROLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES AS (DK) | 2024-05-08 | — | — | EP | disclosed |
| EP-3594335-B1 | CARBOHYDRATE BINDING MODULE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | NOVOZYMES AS (DK) | 2024-05-01 | — | — | EP | disclosed |
| EP-1881078-A1 | METHOD FOR PRODUCING GLUCURONIC ACID AND/OR GLUCURONOLACTONE | Ensuiko Sugar Refining Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-7125984-B2 | For degradation by fucoidan deacetylases, glucuronidases, and fucosidases | TAKARA BIO INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060166335-A1 | Glucuronofucan sulfate | TAKARA BIO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| US-20030186389-A1 | Glucuronofucan sulfate | TAKARA BIO INC. (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1277834-A1 | GLUCURONOFUCAN SULFATE | TAKARA BIO INC. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186389-A1 | Glucuronofucan sulfate | GUSB, GALE, ENGASE | CA2 2019/4885CA9 1276/4885CA12 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.